Soundmark Wealth Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Soundmark Wealth Management’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,966	Closed	-$23.8K	–	62
2023 Q1	$23.8K	Hold	1,966	–	–	0.01%	56
2022 Q4	$8.94K	Hold	1,966	–	–	0.01%	58
2022 Q3	$13K	Hold	1,966	–	–	0.01%	56
2022 Q2	$21K	Hold	1,966	–	–	0.02%	56
2022 Q1	$38K	Hold	1,966	–	–	0.03%	57
2021 Q4	$71K	Sell	1,966 -1,923	-49%	-$109K	0.05%	57
2021 Q3	$286K	Sell	3,889 -384	-9%	-$29.6K	0.1%	60
2021 Q2	$595K	Buy	+4,273	New	+$751K	0.24%	38

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soundmark Wealth Management's SGTX Position: Q2 2023 in Review

Soundmark Wealth Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 1,966 shares — an estimated $23.8K sold.

Soundmark Wealth Management first reported a position in SGTX in Q2 2021 and held it in 8 quarters. The position peaked at $595K in Q2 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Soundmark Wealth Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Soundmark Wealth Management sold 1,966 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.8K.
Soundmark Wealth Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Soundmark Wealth Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $595K in Q2 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Soundmark Wealth Management's 13F filing for Q2 2023, filed 14 Jul 2023.